Parabilis Medicines
Cambridge, Massachusetts, United States · Biopharma, Biotechnology, Healthcare
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blo
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 170
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (PBLS)
- Website
- parabilismed.com
- Company page
Recent activity at Parabilis Medicines
- : Parabilis Medicines Appoints Craig Tendler as Director
- : Parabilis Medicines secures $305 million in Series F funding led by RA Capital Management to advance FOG-001 clinical development and support its innovative Helicon platform.
- : Parabilis Medicines Appoints Fawzi Benzaghou as Chief Medical Officer
- : Parabilis Medicines Announces Corporate Name Change and Unveils Helicon Platform for Drug Discovery
- : FogPharma announced a $145 million Series E financing round led by Nextech Invest to support ongoing clinical development of FOG-001 and accelerate Helicon peptide portfolio.
- : FOG PHARMACEUTICALS
- : Fogpharma Announces $178 Million Series D Financing To Advance Pipeline Of First-In-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
- : FOG PHARMACEUTICALS, INC.
- : FOG PHARMACEUTICALS, INC.
- : FOG PHARMACEUTICALS, INC.
Parabilis Medicines funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Series F | $305.0M |
| Mar 2024 | Series E | $145.0M |
| Dec 2022 | Venture | $178.0M |
| Nov 2022 | Series D | $178.0M |
| Jan 2021 | Venture | $23.3M |
Leadership
- Mathai Mammen, Chairman, CEO and President
- Gregory Verdine, Executive Officer, Director
- Jeffrey Leerink, Director
- Edward Fitzgerald, Director
- Leon Chen, Director
- Krishna Yeshwant, Director
- Barbara Weber, Director
Verified email and direct lines for Parabilis Medicines’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Parabilis Medicines files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Parabilis Medicines in the news
- Regeneron Expands Conjugate Platform Strategy Through Parabilis Medicines Collaboration - BioPharm International (May 18, 2026)
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors - GlobeNewswire (Oct 24, 2026)
- Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Business Wire (May 18, 2026)
- Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire (Nov 12, 2026)
- Parabilis Medicines to Present Updated Clinical Data for - GlobeNewswire (Oct 19, 2026)
- Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewswire (Sep 01, 2026)
Companies similar to Parabilis Medicines
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Retension Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Parabilis Medicines: questions and answers
What does Parabilis Medicines do?
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blo
Where is Parabilis Medicines headquartered?
Parabilis Medicines is headquartered in Cambridge, Massachusetts, United States.
How many employees does Parabilis Medicines have?
Parabilis Medicines has about 170 employees.
Has Parabilis Medicines raised funding?
Yes. Fundz has recorded 5 funding events for Parabilis Medicines. The most recent, Series F of $305.0M, was in Jan 2026.
Who leads Parabilis Medicines?
Mathai Mammen is a Chairman, CEO and President at Parabilis Medicines.
What is the latest news on Parabilis Medicines?
On Aug 25, 2026, Parabilis Medicines Appoints Craig Tendler as Director
Is Parabilis Medicines a public company?
Yes. Parabilis Medicines is publicly traded under the ticker PBLS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy